Associated Genetic Biomarkers
MAGEC1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains MAGEC1 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with MAGEC1 status in the inclusion eligibility criteria most commonly target multiple myeloma .
The most frequent alteration to serve as an inclusion eligibility criterion is MAGEC1 Expression .
Ct7/mage-a3/wt1 mrna-electroporated lcs, autologous hematopoietic stem cell transplantation, and lenalidomide are the most frequent therapies in trials with MAGEC1 as an inclusion criteria .
Significance of MAGEC1 in Diseases
Multiple Myeloma +
MAGEC1 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAGEC1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.